相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients
Kazutaka Hosoya et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria
Tadashi Sakaguchi et al.
RESPIRATORY INVESTIGATION (2019)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat et al.
ANNALS OF ONCOLOGY (2016)
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
Ross Stewart et al.
CANCER IMMUNOLOGY RESEARCH (2015)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
